NCT05730907View on ClinicalTrials.gov

Efficacy and Clinical Outcomes of Levosimendan in E-CPR

UnknownOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Cardiogenic ShockExtracorporeal Membrane Oxygenation Complication
Interventions
DRUG

Levosimendan

examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR

Trial Locations (1)

3050

RECRUITING

Hamad medical corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT05730907 - Efficacy and Clinical Outcomes of Levosimendan in E-CPR | Biotech Hunter | Biotech Hunter